{"id":637055,"date":"2023-02-06T19:34:02","date_gmt":"2023-02-06T19:34:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=637055"},"modified":"2023-02-06T19:34:02","modified_gmt":"2023-02-06T19:34:02","slug":"raynauds-disease-clinical-trials-key-companies-emerging-therapies-a-drug-pipeline-analysis-report-2023-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/raynauds-disease-clinical-trials-key-companies-emerging-therapies-a-drug-pipeline-analysis-report-2023-delveinsight_637055.html","title":{"rendered":"Raynaud\u2019s Disease Clinical Trials, Key Companies, Emerging Therapies | A Drug Pipeline Analysis Report 2023 | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1675680755.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Raynaud&rsquo;s Disease Clinical Trials, Key Companies, Emerging Therapies | A Drug Pipeline Analysis Report 2023 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1675680755.jpeg\" alt=\"Raynaud&rsquo;s Disease Clinical Trials, Key Companies, Emerging Therapies | A Drug Pipeline Analysis Report 2023 | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cRaynaud\u2019s Disease- Pipeline Insight, 2023\u201d report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Raynaud\u2019s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&#8216;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/raynauds-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Raynaud&rsquo;s Disease Pipeline Insight 2023<\/a>&#8216;<\/strong> report provides comprehensive global coverage of available, marketed, and pipeline Raynaud&rsquo;s Disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Raynaud&rsquo;s Disease pipeline domain.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a sample report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/raynauds-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Raynaud&rsquo;s Disease Pipeline<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Raynaud&rsquo;s Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Over <strong>5+<\/strong> Raynaud&rsquo;s Disease pipeline therapies are in various stages of development, and their anticipated acceptance in the Raynaud&rsquo;s Disease market would significantly increase market revenue.&nbsp;<\/li>\n<li>Leading Raynaud&rsquo;s Disease companies developing novel drug candidates to improve the Raynaud&rsquo;s Disease treatment landscape include Gesynta Pharma, United Therapeutics, and others.<\/li>\n<li>Promising Raynaud&rsquo;s Disease pipeline therapies in various stages of development include <strong>GS 248, Treprostinil,<\/strong> and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Raynaud&rsquo;s Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Raynaud&rsquo;s phenomenon is a problem that causes decreased blood flow to the fingers. In some cases, it also causes less blood flow to the ears, toes, nipples, knees, or nose. This happens due to spasms of blood vessels in those areas. The spasms happen in response to cold, stress, or emotional upset.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Raynaud&rsquo;s can occur on its own, known as primary form. Or it may happen along with other diseases, known as secondary form. The exact cause of Raynaud&rsquo;s is unknown. It is possible that some blood disorders may cause Raynaud&rsquo;s by increasing the blood thickness. This may happen due to excess platelets or red blood cells. Or special receptors in the blood that control the narrowing of the blood vessels may be more sensitive.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Symptoms can occur a bit differently in each person. Common symptoms include: Fingers that turn pale or white then blue when exposed to cold, or during stress or emotional upset, then red when the hands are warmed, hands that may become swollen and painful when warmed, sores on the finger pads develop, in severe cases, gangrene in the fingers that causes infection or needs amputation, this is rare.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Raynaud&#8217;s phenomenon treatment depend on symptoms, age and general health. It also depend on how severe the condition is. There is no cure for Raynaud&rsquo;s phenomenon, but it can be managed with proper treatment. The complications of Raynaud&rsquo;s phenomenon is in rare cases, sores on finger pads may occur. These sores may progress to gangrene. In rare cases, gangrene may lead to finger amputation. For most people living with Raynaud&rsquo;s, it is more of an inconvenience than a serious problem.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Avoiding triggers, primarily cold, can reduce the spasms that lead to symptoms. If there is an underlying cause, such as scleroderma or lupus, it may be more difficult to manage attacks. Managing Raynaud&rsquo;s includes avoiding cold, dressing warmly, and stopping smoking.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/raynauds-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Raynaud&rsquo;s Disease Pipeline Analysis<\/a>: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Treprostinil: United Therapeutics<\/strong><\/p>\n<p style=\"text-align: justify;\">Treprostinil is an investigational drug being developed by United Therapeutics. Currently, the drug is in Early Phase I for the treatment of Raynaud&#8217;s phenomenon. Treprostinil, basically acts as a platelet aggregation inhibitor.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about the emerging Raynaud&rsquo;s Disease drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/raynauds-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Raynaud&rsquo;s Disease Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Raynaud&rsquo;s Disease Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Gesynta Pharma<\/li>\n<li>United Therapeutics<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Raynaud&rsquo;s Disease Pipeline Therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>GS 248<\/li>\n<li>Treprostinil<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Raynaud&rsquo;s Disease Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>By development stage<\/li>\n<li>By product type<\/li>\n<li>By route of administration<\/li>\n<li>By molecule type<\/li>\n<li>By MOA type&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Raynaud&rsquo;s Disease Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage:<\/strong>&nbsp;Global&nbsp;<\/li>\n<li><strong>Key Raynaud&rsquo;s Disease Companies:<\/strong> Gesynta Pharma, United Therapeutics, and others<\/li>\n<li><strong>Key Raynaud&rsquo;s Disease Pipeline Therapies:<\/strong> GS 248, Treprostinil, and others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Find out more about the Raynaud&rsquo;s Disease treatment options in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/raynauds-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Raynaud&rsquo;s Disease Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Overview<\/p>\n<p style=\"text-align: justify;\">4. Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">5. Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">6. Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\">7. Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\">8. Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">9. Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">11. Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\">13. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">14. Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">15. Appendix<\/p>\n<p style=\"text-align: justify;\">16. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Other Trending Reports:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Asthma Diagnostic Devices Market<\/li>\n<li>Chronic Obstructive Pulmonary Disease Treatment Devices Market<\/li>\n<li>Airway Management Devices Market<\/li>\n<li>Cough Assist Devices Market<\/li>\n<li>Pulse Oximeters Market<\/li>\n<li>Hemodialysis Catheter Devices Market<\/li>\n<li>Chronic Spontaneous Urticaria Market&nbsp;<\/li>\n<li>Gender Dysphoria Market<\/li>\n<li>Germany Healthcare Outlook<\/li>\n<li>Biopsy Devices Pipeline Insight<\/li>\n<li>Bacterial Conjunctivitis Market<\/li>\n<li>Infliximab Biosimilar Insight<\/li>\n<li>Eosinophilic Asthma Market<\/li>\n<li>Cushing Syndrome Market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Contact Us<\/strong><\/p>\n<p style=\"text-align: justify;\">Kritika Rehani<\/p>\n<p style=\"text-align: justify;\">info@delveinsight.com&nbsp;<\/p>\n<p style=\"text-align: justify;\">+1(919)321-6187&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=raynauds-disease-clinical-trials-key-companies-emerging-therapies-a-drug-pipeline-analysis-report-2023-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=raynauds-disease-clinical-trials-key-companies-emerging-therapies-a-drug-pipeline-analysis-report-2023-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s, \u201cRaynaud\u2019s Disease- Pipeline Insight, 2023\u201d report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Raynaud\u2019s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/raynauds-disease-clinical-trials-key-companies-emerging-therapies-a-drug-pipeline-analysis-report-2023-delveinsight_637055.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-637055","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/637055","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=637055"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/637055\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=637055"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=637055"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=637055"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}